Aditxt, Inc. reported a net loss of $16.2 million for the first quarter of 2026, a significant increase from the $5.9 million loss recorded in the same period of the previous year. The company's revenue rose to $12,159, up from $1,018 in the first quarter of 2025, primarily attributed to the acquisition of Ignite Proteomics, LLC. The cost of goods sold also increased, totaling $9,291 compared to $734 a year earlier. Despite the rise in revenue, the company continues to face substantial operating losses, with total operating expenses decreasing to $4.4 million from $5.6 million year-over-year, largely due to reduced general and administrative costs.
In terms of strategic developments, Aditxt completed the acquisition of Ignite on March 11, 2026, exchanging 36,000 shares of its newly created Preferred A-2 Shares for 100% of Ignite's equity interests. This acquisition is expected to enhance Aditxt's capabilities in immune modulation therapies. The company also reported a significant increase in derivative liabilities, which rose to $35.5 million as of March 31, 2026, reflecting changes in the fair value of its financial instruments.
Operationally, Aditxt's cash position has deteriorated, with cash and cash equivalents dropping to $268,852 from $3.2 million at the end of 2025. The company reported a working capital deficit of $12.5 million and an accumulated deficit of $225.8 million. As of March 31, 2026, Aditxt had 20,196 shares of Series A-1 Convertible Preferred Stock outstanding, with a total of 62,762 shares of preferred stock issued. The company is actively seeking additional capital to fund its operations and clinical studies, indicating a need for significant financial resources to continue its business.
Looking ahead, Aditxt faces challenges related to its Nasdaq listing status, having received a determination letter from Nasdaq regarding potential delisting due to non-compliance with minimum bid price requirements. The company has requested a hearing to appeal this decision. Aditxt's management has expressed concerns about its ability to continue as a going concern, emphasizing the need for substantial capital to support ongoing operations and product development. The company is exploring various financing options, including equity and debt offerings, to address its financial needs.
About Aditxt, Inc.
Aditxt, Inc. develops and commercializes innovative health technologies through a collaborative ecosystem that integrates licensing, development, and commercialization. Its portfolio includes immune modulation therapies, precision health diagnostics, and mitochondrial DNA-based biomarker platforms targeting autoimmune diseases, cancer, and infectious diseases. The company partners with research institutions and healthcare providers to advance personalized and population health solutions, leveraging proprietary technologies and a systemized approach to transform promising innovations into scalable, market-ready products.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov